CD274 and non-small cell lung carcinoma: In advanced-stage NSCLC, 2 standard treatments are commonly used: ICI monotherapy or a combination of ICI with chemotherapy (chemo-ICI), depending on the level of PD-L1 expression and the patient’s clinical features (eg, age).34 Subgroup analysis from the KEYNOTE042 trial35 revealed that treatment-naive patients with PD-L1 (TPS) ranging from 1% to 49% had a response rate of 17% with pembrolizumab monotherapy.